Status and phase
Conditions
Treatments
About
The main clinical goal of NAC is to down-stage the primary tumor for BCS,yet BCS after NAC has been associated with significantly higher ipsilateral breast tumor recurrences.The accuracy of breast tumor excision in BCS can dramatically reduce IBTR.The main reseason of IBTR might be the uncertain shrinkage modes of the breast cancer after NAC.This clinical trial is firstly carried out to make clear the shrinkage modes of the primary tumor after 3 cycles and whole cycles of NAC,respectively,with whole-mount serial section(WMSS) and three-dimensional(3D) pathological reconstruction of the residual tumor.The second objective is to investigate the predictive value of 3D MRI reconstruction for the shrinkage modes of the primary tumor after NAC.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Female patients,locally advanced breast cancer,age ≥18 years.
Histologically confirmed invasive adenocarcinoma of the breast.
Primary palpable disease confined to a breast and axilla on physical examination. For patients without clinically suspicious axillary adenopathy, the primary tumor must be larger than 2 cm in diameter by physical exam or imaging studies (clinical T2-T3, N0-N1, M0). For patients with clinically suspicious axillary adenopathy, the primary breast tumor can be any size (clinical T1-3, N1-2, M0). (T1N0M0 lesions are excluded.)
Patients without clearly defined palpable breast mass or axillary lymph nodes but radiographically measurable tumor masses are acceptable. Accepted procedures for measuring breast disease are mammography, MRI, and breast ultrasound. This will need to be re-evaluated after 3 cycles and prior to surgery.
ECOG 0 or 2
No distant metastasis, as documented by complete staging workup ≤6 weeks prior to initiation of study treatment.
No previous treatment for breast cancer.
Adequate hematologic function with:
Absolute neutrophil count (ANC) >1500/μL. Platelets ≥100,000/μL. Hemoglobin ≥10 g/dL.
Adequate hepatic function with:
Serum bilirubin ≤ the institutional upper limit of normal (ULN). Aspartate aminotransferase (AST) ≤2.5 x institutional ULN. Alanine aminotransferase (ALT) ≤2.5 x institutional ULN.
Adequate renal function with serum creatinine ≤1.5 x ULN.
Planned primary systemic (neoadjuvant) chemotherapy and surgical resection of residual primary tumor (mastectomy or lumpectomy/breast conservation) following completion of neoadjuvant chemotherapy
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
4 participants in 2 patient groups
Loading...
Central trial contact
Yong-sheng Wang, MD; Tao Yang, MD
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal